% | $
Quotes you view appear here for quick access.

Amgen Inc. Message Board

  • mcj96 mcj96 Apr 24, 2013 7:34 PM Flag

    AMGN's rev growth estimate for 2014 is only..........."2%"..............not good

    Is AMGN another LLY ? ........S V N at less than 1x 2014 rev estimates and growing over 80% annually is a far more attractive play IMHO, especially given that they will launch Krystexxa in the EU 2H13, followed by Japan. Dr Meeker and SVNT will also raise the price of Krystexxa by approximately 2-3 fold before year end to align it more appropriately for the acute RCG tophi market. They already raised the price of Krystexxa by 67% in January....... In addition, SVNT will release Dialysis Study results 3Q13. If they mirror positive P3 Trial data....SVNT and Dr Meeker will be able to...... again double the price of Krystexxa for its additional disease benefit. Good luck to all.

156.35-2.64(-1.66%)May 3 4:00 PMEDT